Biosimilars 2019 will showcase the current year’s gathering is New Horizons in Biosimilars and Drug Delivery which will give a worldwide stage to talk of present and future of Biosimilars and drug delivery. Biosimilars are neither generic medicines nor novel treatments. Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (MAbs), are playing an increasingly important role in global healthcare. The phenomenally complex manufacturing process involved in making biosimilars is really leading contemporary science in this field and could potentially revolutionize the treatment of some conditions.
Biosimilars versus generic drugs Biosimilars and generic drugs are versions of brand-name drugs. But biosimilars are not generics, and there are important differences between biosimilars and generic drugs. Both biosimilars and generics are approved through different abbreviated pathways. The manufacturer of a generic drug must demonstrate that the generic is bioequivalent to the brand name drug. Biosimilar manufacturers must demonstrate that the biosimilar is highly similar to the reference product. Biosimilars drugs should show there is no clinically meaningful differences between the biosimilar and the reference product in terms of safety and effectiveness.